Aspirin Treatment Effective Against Pre-eclampsia – But Must Be Started Early
Guidelines on pre-eclampsia prevention in various countries (e.g. Australia, Canada, France, Germany, Italy, UK) recommend the administration of low-dose aspirin in all pregnancies that are at risk, starting during the first trimester, or at least before week 16. In addition, Calcium is recommended for women with low dietary intake/calcium deficiency in local guidelines in France, Australia and New Zealand for pre-eclampsia prevention.
Treatment with low doses of aspirin (acetylsalicylic acid, ASA) during pregnancy has been shown to reduce the risk of pre-eclampsia. Although meta study data initially suggested that the benefits are modest (Duley, 2007), it is now understood that the time at which aspirin treatment is commenced is of principle importance (Bujold, 2010). The inclusion of results from pregnancies where aspirin has been administered at a late stage of pregnancy compromised the earlier meta-studies, and hid the clear benefit that administration before 16 weeks provides. In a recent meta study (Roberge et al, 2012) it was concluded that low-dose aspirin administrated at or before 16 weeks of gestation provides an 89% reduction in the risk of pre-eclampsia that necessitates delivery before 37 weeks. Research into the efficacy of aspirin therapy continues and should only be pursued at the direction of a medical professional.
PerkinElmer products for pre-eclampsia are not available in all countries. For information on availability please contact your local sales representative.
Information provided within the Overview of Pre-eclampsia is for information purposes only and not intended to be construed as medical guidance. Always contact your healthcare professional for assessment and direction regarding your health.
PerkinElmer does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice.